Floatz logo

Inotersen

Amyloidosis

Brigham and Women's Hospitalnucleic_acidPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Amyloidosis cohort.

Asset / SponsorPhaseRating
Acoramidis
Bayer
Phase 4BBB
Dexasone
Ascentage Pharma Group Inc.
Phase 3BB
Empagliflozin
Columbia University
Phase 4BB
Tafamidis
Pfizer
Phase 4BB
LENALIDOMIDE
Ascentage Pharma Group Inc.
Phase 3BB

View all 34 →

Same molecule, other indications

Inotersen is also rated in:

familial amyloid neuropathyActive
BB
Indicative · Phase 4
70 / 100
View asset →
pregnancy disorderActive
D
Indicative · Unknown
30 / 100
View asset →
hereditary amyloidosisDormant
D
Indicative · Unknown
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →